

Service Profiles

Sue Knights

Senior Information Manager NCIN/NPR

Profiles - Rationale

- Service profiles:
 - Benchmark and assess
 - NHS Trust / multi-disciplinary team (MDT) based
 - Assist clinical teams to reflect on outcomes
 - Assist the commissioners of cancer services to
 - *understand the variation across the MDT's (local service) for both patient experience and patient care.*
 - Indicators included have been
 - *discussed with commissioners and MDT's as being important and form the basis for objective dialogue about clinical practice and service delivery.*

- Service profiles:
 - Developed from similar Breast/Colorectal/ Lung profiles (published Dec 2011, Feb 2013, June 2013)
 - Based on latest nationally available data
 - cancer registration, CWT, NLCA, CPES, HES, Peer Review
 - Part generic, part specialist indicators.
 - Specialist indicators largely drawn from National audits
 - Indicators also incorporate Clinical Lines of Enquiry


Profiles - structure

NCIN / PHE KIT team
(formally Thames Cancer
Registry) co-production

Hosted in the Cancer
Commissioning Toolkit –

Public view – open
access

Professional view -
access registration
required


























www.cancertoolkit.co.uk

Profiles...

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period		
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range			High- est	
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010	
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011	
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011	
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010	
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010	
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010	
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010	
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010	
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011	
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011	
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011	
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011	
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011	
Specialist Team	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11	
	15	Peer review: Proportion of peer review indicators met	SA	85%			89%					NCPR	2010/11
	16	Peer review: are there immediate risks? (4)	SA	No								NCPR	2010/11
	17	Peer review: are there serious concerns? (4)	SA	No								NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%		100%	NLCA	2011	
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer	406				293	0		853	CWT	2010/11	
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%		93%	NLCA	2011	
	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%		100%	NLCA	2011	
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%		79%	NLCA	2011	
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		100%	NLCA	2011	
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		97%	HES	2011	
Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2	
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2	
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12	
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12	
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2	
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011	
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011	
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011	
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011	
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011	
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011	
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.47	NLCA	2011	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12	
	40	Number of survey questions and % of those questions scoring red and green (7)	% Red	0	n/a			0%		78%	CPES	2011/12	
	% Green		0	n/a			0%		69%	CPES	2011/12		

Profiles... rationale

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period		
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range			High- est	
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41		588	NCDR	2010	
	2	Number of NLCA patients - lung cancer	329				191	1		585	NLCA	2011	
	3	Number of NLCA patients - mesothelioma	11				10	0		31	NLCA	2011	
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010	
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010	
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010	
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010	
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010	
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011	
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011	
	11	Number a									NLCA	2011	
	12	Number a									NLCA	2011	
	13	Proportion									NLCA	2011	
Specialist Team	14	Peer review									NCPR	2010/11	
	15	Peer review									NCPR	2010/11	
	16	Peer review									NCPR	2010/11	
	17	Peer review									NCPR	2010/11	
	18	Number a									NLCA	2011	
Throughput and pathology	19	Number c									CWT	2010/11	
	20	Number a									NLCA	2011	
	21	Number a									NLCA	2011	
	22	Number a									NLCA	2011	
	23	Number a									NLCA	2011	
	24	Estimated									HES	2011	
Waiting times	25	Q2 2012/									CWT	2012/13 Q2	
	26	Q2 2012/									CWT	2012/13 Q2	
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12	
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12	
Practice	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2	
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011	
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011	
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011	
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011	
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011	
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011	
	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12	
Outcomes and Recovery	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57		1.49	NLCA	2011	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40		2.67	NLCA	2011	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12	
	40	% Red	0	n/a				0%			78%	CPES	2011/12
	41	Number of survey questions and % of those questions scoring red and green (7)		n/a				0%			69%	CPES	2011/12

- Assess and benchmark a wide range of information at organisation level
- Allows a ‘at a glance’ assessment of an organisation

- Assess and benchmark a wide range of information at organisation level
- Allows a 'at a glance' assessment of an organisation

Profile anatomy

Section	#	Indicator	Percentage or rate				Trust rate or percentage compared to England				Source	Period
			No. of patients/cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Lowest	Range	Highest		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41		588	NCDR	2010
	2	Number of NLCA patients - lung cancer	329				19	1		585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0		31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%		100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%		46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%		34%	NCDR	2010
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%		72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%		100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%		68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%		30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%		80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%		100%	NLCA	2011
	14	Peer review: Doe									NCPR	2010/11
Specialist Team	15	Peer review: Pro										
	16	Peer review: are										
	17	Peer review: are										
Throughput and pathology	18	Number and prop										
	19	Number of urgent										
	20	Number and prop										
	21	Number and prop										
	22	Number and prop										
Waiting times	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%		100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%		97%	HES	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%		100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%		100%	CWT	2012/13 Q2
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%		46%	CWT	2011/12
Practice	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%		76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%		100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%		100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%		38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%		45%	NLCA	2011
Outcomes and Recovery	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%		100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%		100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%		100%	NLCA	2011
	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%		68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.1	0.57		1.49	NLCA	2011
Patient Experience - CPES (8)	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.1	0.40		2.67	NLCA	2011
	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%		100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)	0	n/a				0%		78%	CPES	2011/12
	41			n/a				0%		69%	CPES	2011/12

Indicator descriptions (41)

Numbers, rates, and comparators

Spine chart & range of data

Sources & Dates

Profile anatomy

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England			Source	Period
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range		
Size	1	Number of newly diagnosed lung cancer patients per year, 2010							588	NCDR	2010
	2	Number of NLCA patients - lung cancer							585	NLCA	2011
	3	Number of NLCA patients - mesothelioma							31	NLCA	2011
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+							75%	NCDR	2010
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	100%	NCDR	2010
	6	Patients (from #5) with recorded ethnicity which is not White-British							46%	NCDR	2010
	7	Patients (from #1) who are Income Deprived (2)							34%	NCDR	2010
	8	Male patients (from #1)							72%	NCDR	2010
	9	Number and proportion of patients (from #2) with a stage assigned							100%	NLCA	2011
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned							68%	NLCA	2011
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned							30%	NLCA	2011
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	80%	2%	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)	CA	Var						NCPR	2010/11
	15	Pe								NCPR	2010/11
Specialist Team	16	Pe								NCPR	2010/11
	17	Pe								NCPR	2010/11
Throughput and pathology	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	70%	0%	100%	NLCA	2011
	19	Number of urgent GP referrals for suspected cancer	406				293	0	853	CWT	2010/11
	20	Number and proportion of pati							93%	NLCA	2011
	21	Number and proportion of pati							100%	NLCA	2011
	22	Number and proportion of pati							79%	NLCA	2011
	23	Number and proportion of pati							100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	97%	HES	2011
Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	98%	92%	98%	97%	88%	100%	CWT	2012/13 Q2
	26	Q2 20								CWT	2012/13 Q2
	27	Urgen								CWT	2011/12
	28	Cases								CWT	2011/12
Practice	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	100%	100%	99%	91%	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC							38%	NLCA	2011
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC							45%	NLCA	2011
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II							100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy							100%	NLCA	2011
	35	No. and proportion of patients (from #2) with stage IIIB/IV, PS 0-1 and confirmed SCLC receiving chemotherapy	28	50%	44%	74%	55%	0%	100%	NLCA	2011
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appoi							68%	PBR SUS	2011/12
	37	NLCA: Median survival in days and adjusted hazard ratio for morta							1.49	NLCA	2011
	38	NLCA: Proportion of patients surviving at one year and adjusted oc							2.67	NLCA	2011
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)							100%	CPES	2011/12
	40	Number of survey questions and % of those questions scoring red and green (7)							78%	CPES	2011/12

Size – no. patients diagnosed

**Patient demographics
(including stage/PS)**

Specialist team – Peer Review concerns and CNS coverage

Throughput and pathology – patient breakdown

Waiting times performance and conversion/detection rates

Clinical practice

Outcomes and recovery

Patient Experience

Profiles – detail (1)

Section	#	Indicator
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)
	2	Number of NLCA patients - lung cancer
	3	Number of NLCA patients - mesothelioma
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+
	5	Patients (from #1) with recorded ethnicity
	6	Patients (from #5) with recorded ethnicity which is not White-British
	7	Patients (from #1) who are Income Deprived (2)
	8	Male patients (from #1)
	9	Number and proportion of patients (from #2) with a stage assigned
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned
	13	Proportion of patients (from #2) with a Performance Status assigned

Profiles – detail (2)

Specialist Team	14	Peer review: Does the specialist team have full membership? (3)
	15	Peer review: Proportion of peer review indicators met
	16	Peer review: are there immediate risks? (4)
	17	Peer review: are there serious concerns? (4)
	18	Number and proportion of patients (from #2) seen by CNS (5)
Throughput and pathology	19	Number of urgent GP referrals for suspected cancer
	20	Number and proportion of patients (from #2) with confirmed NSCLC
	21	Number and proportion of patients (from #2) with confirmed SCLC
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis
	24	Estimated proportion of tumours with emergency presentations [experimental]

Profiles – detail (3)

Waiting times	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]
	29	Q2 2012/13: First treatment began within 31 days of decision to treat
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy

Profiles – detail (4)

Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	
	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	
Patient Experience - CPES (8)	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	
	40	Number of survey questions and % of those questions scoring red and green (7)	% Red
	41		% Green

Profiles development

- **2013/2014**
 - Existing profiles converted to web format – Sept 2013
 - 4 further service profiles released (OG, Sarcoma, Gynaecology, Head & Neck) – Sept 2013
 - CCG profiles released – Dec 2013

Profiles development

- **2014/2015**
 - Develop 4 further service profiles (Urology, Haematology, Skin, CNS) – Sept 2014
 - Headline narrative reports - 2014

Further thoughts

Over to you